Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient

Respiratory syncytial virus (RSV) is an important community-acquired pathogen that can cause significant morbidity and mortality in patients who have compromised pulmonary function, are elderly, or are immunosuppressed. This paper describes a 70-year-old man with a remote history of heart transplant...

Full description

Saved in:
Bibliographic Details
Main Authors: J. L. Grodin, K. S. Wu, E. E. Kitchell, J. Le, J. D. Mishkin, M. H. Drazner, D. W. Markham
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Case Reports in Cardiology
Online Access:http://dx.doi.org/10.1155/2012/723407
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832552009751855104
author J. L. Grodin
K. S. Wu
E. E. Kitchell
J. Le
J. D. Mishkin
M. H. Drazner
D. W. Markham
author_facet J. L. Grodin
K. S. Wu
E. E. Kitchell
J. Le
J. D. Mishkin
M. H. Drazner
D. W. Markham
author_sort J. L. Grodin
collection DOAJ
description Respiratory syncytial virus (RSV) is an important community-acquired pathogen that can cause significant morbidity and mortality in patients who have compromised pulmonary function, are elderly, or are immunosuppressed. This paper describes a 70-year-old man with a remote history of heart transplantation who presented with signs and symptoms of pneumonia. Chest computed tomography (CT) imaging demonstrated new patchy ground glass infiltrates throughout the upper and lower lobes of the left lung, and the RSV direct fluorescence antibody (DFA) was positive. The patient received aerosolized ribavirin, one dose of intravenous immunoglobulin, and one dose of palivizumab. After two months of followup, the patient had improved infiltrates on chest CT, improved pulmonary function testing, and no evidence of graft rejection or dysfunction. There are few data on RSV infections in heart transplant patients, but this case highlights the importance of considering this potentially serious infection and introduces a novel method of treatment.
format Article
id doaj-art-4aceb67c263e443fb499441f48cb52d9
institution Kabale University
issn 2090-6404
2090-6412
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Case Reports in Cardiology
spelling doaj-art-4aceb67c263e443fb499441f48cb52d92025-02-03T05:59:52ZengWileyCase Reports in Cardiology2090-64042090-64122012-01-01201210.1155/2012/723407723407Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant RecipientJ. L. Grodin0K. S. Wu1E. E. Kitchell2J. Le3J. D. Mishkin4M. H. Drazner5D. W. Markham6Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USADepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USADepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USADepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USADepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USADepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USADepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USARespiratory syncytial virus (RSV) is an important community-acquired pathogen that can cause significant morbidity and mortality in patients who have compromised pulmonary function, are elderly, or are immunosuppressed. This paper describes a 70-year-old man with a remote history of heart transplantation who presented with signs and symptoms of pneumonia. Chest computed tomography (CT) imaging demonstrated new patchy ground glass infiltrates throughout the upper and lower lobes of the left lung, and the RSV direct fluorescence antibody (DFA) was positive. The patient received aerosolized ribavirin, one dose of intravenous immunoglobulin, and one dose of palivizumab. After two months of followup, the patient had improved infiltrates on chest CT, improved pulmonary function testing, and no evidence of graft rejection or dysfunction. There are few data on RSV infections in heart transplant patients, but this case highlights the importance of considering this potentially serious infection and introduces a novel method of treatment.http://dx.doi.org/10.1155/2012/723407
spellingShingle J. L. Grodin
K. S. Wu
E. E. Kitchell
J. Le
J. D. Mishkin
M. H. Drazner
D. W. Markham
Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient
Case Reports in Cardiology
title Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient
title_full Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient
title_fullStr Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient
title_full_unstemmed Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient
title_short Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient
title_sort respiratory syncytial virus pneumonia treated with lower dose palivizumab in a heart transplant recipient
url http://dx.doi.org/10.1155/2012/723407
work_keys_str_mv AT jlgrodin respiratorysyncytialviruspneumoniatreatedwithlowerdosepalivizumabinahearttransplantrecipient
AT kswu respiratorysyncytialviruspneumoniatreatedwithlowerdosepalivizumabinahearttransplantrecipient
AT eekitchell respiratorysyncytialviruspneumoniatreatedwithlowerdosepalivizumabinahearttransplantrecipient
AT jle respiratorysyncytialviruspneumoniatreatedwithlowerdosepalivizumabinahearttransplantrecipient
AT jdmishkin respiratorysyncytialviruspneumoniatreatedwithlowerdosepalivizumabinahearttransplantrecipient
AT mhdrazner respiratorysyncytialviruspneumoniatreatedwithlowerdosepalivizumabinahearttransplantrecipient
AT dwmarkham respiratorysyncytialviruspneumoniatreatedwithlowerdosepalivizumabinahearttransplantrecipient